【摘要】 目的 评估吉非替尼治疗终末期(PS评分≥3分)非小细胞肺癌(NSCLC)的临床效果和生活质量改善情况。 方法 2008年5月-2010年6月共收治终末期NSCLC患者40例,其中19例患者采用吉非替尼治疗(治疗组),21例采用支持治疗+中药治疗(对照组)。 结果 治疗6个月后,治疗组19例患者中,CR 1例,PR 5例,SD 10例,PD 3例。治疗组有效率为31.5%(6/19),临床受益率为84.2%(16/19)。对照组21例中,SD 5例,PD 16例,无CR。对照组有效率为23.8%(5/21),临床受益率为 23.8%(5/21)。两组间有效率和临床受益率比较,差异均有统计学意义(P lt;0.05)。治疗组中位生存期为13.2个月,对照组中位生存期为4.5个月。 结论 吉非替尼可延长NSCLC患者的生存期,改善其生活质量。
【Abstract】 Objective To evaluate the curative effect and life improvement of gefitinib on non-small cell lung cancer (NSCLC) which in the end stage. Methods Forty patients with end-stage NSCLC were treated from May 2008 to June 2010. Nineteen patients of them were treated with gefitinib (treatment group), 21 patients were treated with supportive care and traditional Chinese medicine treatment (control group). Results Six months after treatment, there are one patient with CR, five patients with PR, 10 patients with SD and three patients with PD in the treatment group. The effective rate of treatment group was 31.5% (6/19), clinical benefit rate was 84.2% (16/19). There are five patients with SD, 16 patients with PD, and no one with CR in the control group. The effective rate of the control group was 23.8% (5/21), clinical benefit rate was 23.8% (5/21). The differences of effective rate and clinical benefit rate between two groups were statistically significant (P lt;0.05). The median survival period of the treatment group and control group were 13.2 and 4.5 months respectively. Conclusion Gefitinib can extend the lifetime of NSCLC patients and improve their quality of life.
Citation: LIU Dingyi,ZHU Li,ZHANG Jiliang,LIU Hong. Clinical Obsevation of Gefitinib on Mutational Unknown Non-small Cell Lung Cancer in End Stage. West China Medical Journal, 2010, 25(8): 1423-1425. doi: Copy